Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. - Wikidata - awgldk - TriplyDB

Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease.

Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease.

http://www.wikidata.org/entity/Q33268021

about

Azathioprine for multiple sclerosis Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug Withdrawal Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan Use of thiopurines in inflammatory bowel disease: Safety issues.Caerulomycin A enhances transforming growth factor-β (TGF-β)-Smad3 protein signaling by suppressing interferon-γ (IFN-γ)-signal transducer and activator of transcription 1 (STAT1) protein signaling to expand regulatory T cells (Tregs)Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease.Do inflammatory bowel disease therapies cause cancer?Knockdown of HPRT for selection of genetically modified human hematopoietic progenitor cells Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer.Predictive factors of clinical response in steroid-refractory ulcerative colitis treated with granulocyte-monocyte apheresis How to Review a Meta-analysis Safety Profile of Thiopurines in Crohn Disease: Analysis of 893 Patient-Years Follow-Up in a Southern China Cohort The long-term risk of continuous immunosuppression using thioguanides in inflammatory bowel disease Change in hematologic indices over time in pediatric inflammatory bowel disease treated with azathioprine Interfering RNA-mediated purine analog resistance for in vitro and in vivo cell selection.Cancer risk in immune-mediated inflammatory diseases (IMID).Are we giving azathioprine too late? The case for early immunomodulation in inflammatory bowel disease.Natural history and complications of IBD.Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease.A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease.Immunomodulators for all patients with inflammatory bowel disease?Lymphoma in inflammatory bowel disease and treatment decisions.Practical guidelines for the use of steroid-sparing agents in the treatment of chronic pruritus.Current concepts in the diagnosis and management of autoimmune hepatitis.The safety of non-biological treatments in Ulcerative Colitis.Safety profile of methotrexate in inflammatory bowel disease.Immune effector cells produce lethal DNA damage in cells treated with a thiopurine Has widespread use of biologic and immunosuppressant therapy for ulcerative colitis affected surgical trends? Results of a questionnaire survey of surgical institutions in Japan.Gut-liver axis plays a role in hepatocarcinogenesis of patients with Crohn's disease.Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study.Predictive factors associated with immunosuppressive agent use in ulcerative colitis: a case-control study.Hepatocellular carcinoma occurring in a young Crohn's disease patient.Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study.Renal cell carcinoma in a patient with cystinosis and inflammatory bowel disease: a case report.Allopurinol in combination with thiopurine induces mucosal healing and improves clinical and metabolic outcomes in IBD.

P2860

Q24242945-0D3FECB6-1912-4251-95AC-62C4514E1436 Q26801119-47758A22-043C-47B6-BBEA-2BF88CC13345 Q26822029-306738E7-4351-44A0-8C2A-9E237354000E Q26829392-261D77A3-06C6-4F53-ACBE-C99D432AFD37 Q33621267-6EA18839-870E-4BE5-B18A-9FC59BD859B3 Q33792909-916CAF0D-B98C-4C5F-804D-6CD726C15C31 Q34078707-0652ECFE-2F3D-4076-B18B-5842EF46B597 Q34613890-15F988F4-2EBC-4CAD-B82F-DC05F1479FEE Q34649263-233F1EF0-F835-4218-A82D-24381AC33493 Q34728470-541468EB-12BA-447B-A92C-263511B9B124 Q34831143-2D8E570B-B12C-4939-9F32-573CC8C47B0B Q34996708-0A9224A8-111F-4F66-B49F-D3BA2B74BC0E Q36195577-6A8D8FA4-1E6E-4F68-9582-AF4D6E608389 Q36443655-9DB711A8-5CBD-4ED7-92F9-C4C55775658E Q36650158-FCA33257-CE40-4424-9D8A-F8EAC9B278C5 Q37001949-E7FC3D10-CE81-406F-814D-E07D80D44C86 Q37153407-54D68D69-31C9-4767-BA70-F2BA424A684B Q37276962-5FDA0E2A-6219-40B9-BAFC-B004F87BAA42 Q37630733-1CFE6788-8F45-42DD-AEE2-F3126BCCEFD2 Q37735878-529CB35C-0F7F-47C9-9F8A-5A80D5900C85 Q37814549-7069F0C4-2DD3-4901-95C5-B56DF62BAB15 Q37823320-6F1C468C-CB5E-4C36-B764-C580594E4FF3 Q38024070-1A5A6215-E4F6-458E-8373-0712BD01CD6F Q38095599-1FCA0A70-CC19-4367-AEB9-D476B12FEC67 Q38609184-4757F01E-F549-4FF4-AE3B-D3C62C84CA90 Q38728164-347A99E8-F9A8-4C51-96D4-4668F14AF675 Q38909929-49689D24-A87C-49B6-AF8C-10E0F833D840 Q39879692-193492BA-B96F-455F-A0CE-26DE82A41C23 Q40431363-92FEB7E8-4561-4247-8A20-473BDDC1E685 Q42871172-7590DC0E-A2CD-4ECE-A18E-C8384BE18807 Q43962565-809E0BBD-7E22-4584-87DF-C4F816B5F7BC Q44984941-1EAAA0AC-6DF9-4AC8-B196-53A0D75D7FB1 Q45948017-474AE257-8978-48C7-A0DA-EC8EDEB05CB2 Q46397135-B01CFC6B-12BE-4637-865D-6637C99A2E3E Q46744631-FD278212-E859-4493-8DC3-82D4CD5B8BB4 Q49292225-5458736F-800D-45DA-9D64-A6A7343A1327

P2860

Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease.

http://www.wikidata.org/entity/Q33268021

description

2007 nî lūn-bûn

@nan

2007 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Meta-analysis of risk of malig ...... in inflammatory bowel disease.

@ast

Meta-analysis of risk of malig ...... in inflammatory bowel disease.

@en

Meta-analysis of risk of malig ...... in inflammatory bowel disease.

@nl

type

label

Meta-analysis of risk of malig ...... in inflammatory bowel disease.

@ast

Meta-analysis of risk of malig ...... in inflammatory bowel disease.

@en

Meta-analysis of risk of malig ...... in inflammatory bowel disease.

@nl

prefLabel

Meta-analysis of risk of malig ...... in inflammatory bowel disease.

@ast

Meta-analysis of risk of malig ...... in inflammatory bowel disease.

@en

Meta-analysis of risk of malig ...... in inflammatory bowel disease.

@nl

P1433

Q33268021-1F1E5A95-39A7-488A-A8F4-53C20F6EA0A4

P1476

Q33268021-1F2E6041-44AC-4BBC-B7CF-0CE594ECEB8E

P2093

Q33268021-13E29B01-09FE-4523-A53D-A1BA079DA3A7

Q33268021-7B3A7717-3EA6-4A5D-AA03-98B97295D650

Q33268021-C64A858A-5214-46BE-9B3D-00DE8A84C0E7

Q33268021-F41EAEE4-66E0-4543-B490-86636DE7F153

Q33268021-FD3E7C67-875F-4F26-A48C-33D75D5E43E7

Q33268021-FDEE3E66-50D5-4B96-8D53-ED00F54EEBCC

P2860

Q33268021-030D65DF-76C6-463B-A29B-D8039AA827D2

Q33268021-07B5F1FF-70D6-40B4-9F4C-52B5ABB2FAB8

Q33268021-193D5789-8C29-45E1-AE13-0EF90B222202

Q33268021-220369B0-B517-448D-97F9-C36E51E4DAC6

Q33268021-3C6F9542-01D2-4672-8FEC-0B20A9CDB703

Q33268021-4BB9FB71-CD94-40BA-A7F8-6E58AA5BB34B

Q33268021-4C8906DA-B061-497E-95E1-3CEC31DEC257

Q33268021-4F39A944-5E52-4A71-B428-1BEAADAB98D7

Q33268021-57B4B276-9592-4F9B-AE24-DEF16BF577D3

Q33268021-62C14469-BBB3-48AC-BD93-B2EC1BDD98F8

P304

Q33268021-BE3E0543-ABF7-4A86-8A4A-496D5A9D924B

P31

Q33268021-0C9655C7-B390-4592-9AF9-47673F46A1E5

Q33268021-ea6a4610-3f73-4ad9-8d12-329da3ee4256

P356

Q33268021-3E13CD6C-BA6A-4978-80DB-FD7EA7B759A7

P407

Q33268021-92456D04-3ABA-4382-B007-D46209D1A5E1

P433

Q33268021-C33F7DA5-7E58-47D3-AF03-F72C8EBF5B54

P478

Q33268021-AB381119-DE40-428D-8E65-CA7645DF6547

P577

Q33268021-3C276DE3-AEBD-4A63-8457-C19FA189EE29

P698

Q33268021-394122D8-6E2F-4630-A140-7A294EF1C8E7

P921

Q33268021-3ECEF34B-67B1-43DB-8CD1-DBB1AAB13C66

Q33268021-60EADC44-717A-460D-BB99-AAF7444B3EB1

Q33268021-89DACAF5-8A22-41D5-A1A4-3F4710AA3B83

P356

P1433

Annals of Pharmacotherapy

P1476

Meta-analysis of risk of malig ...... in inflammatory bowel disease.

@en

P2093

Hirotoshi Echizen

http://www.w3.org/2001/XMLSchema#string

Hiroyasu Ogata

http://www.w3.org/2001/XMLSchema#string

Keiko Ohno

http://www.w3.org/2001/XMLSchema#string

Masayuki Hashiguchi

http://www.w3.org/2001/XMLSchema#string

Ryuichi Ogawa

http://www.w3.org/2001/XMLSchema#string

Yukari Masunaga

http://www.w3.org/2001/XMLSchema#string

P2860

Management of Crohn's disease in adults

The risk of colorectal cancer in ulcerative colitis: a meta-analysis

Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine

The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions

Crohn's disease and colorectal cancer

Screening for colorectal cancer in ulcerative colitis: dubious benefits and high costs.

Ulcerative colitis and colorectal cancer. A population-based study.

Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine.

Increased risk of large-bowel cancer in Crohn's disease with colonic involvement.

Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low

P304

21-28

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1345/APH.1H219

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

41

http://www.w3.org/2001/XMLSchema#string

P577

2007-01-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17200426

http://www.w3.org/2001/XMLSchema#string

P921

inflammatory bowel diseases